NextCure  Inc


Prices are adjusted according to historical splits.

NextCure  Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$42.49 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

NextCure  Inc had its IPO on 2019-05-09 under the ticker symbol NXTC.

The company operates in the Healthcare sector and Biotechnology industry. NextCure  Inc has a staff strength of 99 employees.

Stock update

Shares of NextCure  Inc opened at $1.48 at the start of the last trading session i.e. 2023-03-31.

The stocks traded within a range of $1.48 - $1.55, and closed at $1.48.

This is a -0.67% slip from the previous day's closing price.

A total volume of 56,259 shares were traded at the close of the day’s session.

In the last one week, shares of NextCure  Inc have slipped by -8.07%.

NextCure  Inc's Key Ratios

NextCure  Inc has a market cap of $42.49 million, indicating a price to book ratio of 0.2065 and a price to sales ratio of 9.5227.

In the last 12-months NextCure  Inc’s revenue was $0 with a gross profit of $-54199000 and an EBITDA of $-71785000. The EBITDA ratio measures NextCure  Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NextCure  Inc’s operating margin was 0% while its return on assets stood at -22.25% with a return of equity of -37.28%.

In Q4, NextCure  Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

NextCure  Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NextCure  Inc’s profitability.

NextCure  Inc stock is trading at a EV to sales ratio of 1.623 and a EV to EBITDA ratio of 3.0777. Its price to sales ratio in the trailing 12-months stood at 9.5227.

NextCure  Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$184.16 million
Total Liabilities
$9.13 million
Operating Cash Flow
$4.47 million
Capital Expenditure
Dividend Payout Ratio

NextCure  Inc ended 2023 with $184.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $184.16 million while shareholder equity stood at $167.53 million.

NextCure  Inc ended 2023 with $0 in deferred long-term liabilities, $9.13 million in other current liabilities, 28000.00 in common stock, $-261759000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $26.63 million and cash and short-term investments were $159.91 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

NextCure  Inc’s total current assets stands at $163.98 million while long-term investments were $0 and short-term investments were $133.28 million. Its net receivables were $0 compared to accounts payable of $4.27 million and inventory worth $0.

In 2023, NextCure  Inc's operating cash flow was $4.47 million while its capital expenditure stood at $865000.

Comparatively, NextCure  Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

NextCure  Inc stock is currently trading at $1.48 per share. It touched a 52-week high of $5.38 and a 52-week low of $5.38. Analysts tracking the stock have a 12-month average target price of $5.25.

Its 50-day moving average was $1.61 and 200-day moving average was $2.71 The short ratio stood at 3.29 indicating a short percent outstanding of 0%.

Around 875.8% of the company’s stock are held by insiders while 4912.9% are held by institutions.

Frequently Asked Questions About NextCure  Inc

The stock symbol (also called stock or share ticker) of NextCure  Inc is NXTC

The IPO of NextCure  Inc took place on 2019-05-09

Similar Industry Stocks (Biotechnology)

Last Price
Urban One (UONE)
Aclarion Inc (ACONW)
Swiss Re Ltd (SSREY)

Most Active

Last Price
Tesla Inc (TSLA)

Top Gainers

Last Price
Helbiz Inc (HLBZ)

Top Losers

Last Price
Imara Inc (IMRA)


NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.


9000 Virginia Manor Road, Beltsville, MD, United States, 20705